If they put all the MS drugs, and all the cancer drugs, and all the HIV drugs on the same cost-tier plan, they're really not discriminating against one disease group. They're discriminating against anyone who must depend on higher-cost drugs.

Both drugs lower the risk of developing breast cancer by 50%.

There are some exciting new molecular-targeted drugs that are helpful, and we're understanding the molecular biology of lung cancer much better today in helping to design more rational treatments. But unfortunately, the vast majority of people with lung cancer today will die from their disease.

Most women [with ovarian cancer] develop resistance to conventional chemotherapy drugs.

I was diagnosed with breast cancer in 2004.

We are so pleased Dan was recognized for all of his efforts. He enjoys working with the American Cancer Society staff to ensure the safe and timely delivery of the daffodils.